Skip to content

Clinical trials

Prostatic Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Country / region: China Clear all

410 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20052
20072
20083
20101
20112
20124
20136
20145
201511
201613
201711
201817
201915
202027
202133
202226
202344
202466
202561
202660

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting136
Unknown status109
Completed70
Active, not recruiting40
Not yet recruiting37
Terminated10
Enrolling by invitation5
Suspended2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School19
Peking University First Hospital18
Fudan University16
AstraZeneca13
First Affiliated Hospital of Fujian Medical University13
Jiangsu HengRui Medicine Co., Ltd.11
Anhui Provincial Hospital10
Janssen Research & Development, LLC10
RenJi Hospital10
Peking Union Medical College Hospital9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms410
Disease29
Breast Neoplasms24
Ovarian Neoplasms21
Stomach Neoplasms18
Urinary Bladder Neoplasms17
Neoplasm Metastasis16
Pancreatic Neoplasms14
Adenocarcinoma13
Colorectal Neoplasms13

Trials

Showing 76 to 100 of 410. Each trial links to its page on Pharma Observatory.

310 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.